



1FW  
PATENT

Attorney Docket No.: PP001573.0101

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:

Applicants: Derek O'Hagan et al.

Conf. No.: 2374

Serial No.: 09/914,279

Group Art Unit: 1615

Filing Date: 01/09/2002

Examiner: Carlos A. Azpuru

For: MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND  
MICROPARTICLES

**CERTIFICATE OF MAILING**

I hereby certify that this paper is being deposited with the United States Patent and Trademark Office as first class mail in an envelope addressed: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 3-30-07.

By: Sharleen Lane  
Sharleen Lane

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on Form PTO/SB/08, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

**This Information Disclosure Statement is being filed:**

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☐ **before** the mailing date of a first Office Action on the merits.
- ☒ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
  - ☒ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
  - or**
  - ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
  - ☒ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- ☒ Copies of the references listed on the attached Form PTO/SB/08, are enclosed herewith. Reference B3 was also cited in the IDS filed June 17, 2004 and reference B5 was also cited in the IDS filed October 23, 2002.

**EXCEPT THAT:**

- ☐ In view of the voluminous nature of reference @@@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached Form PTO/SB/08 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

**Statement under 37 C.F.R. § 1.97(e)**

- ☒ The undersigned attorney hereby states that each item contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement. A copy of this communication (Partial European Search Report) is enclosed.


**Fees**

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

**Method of Payment of Fees**

- ☐ Attached is a check in the amount of \$ \_\_\_\_\_. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 03-1664 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 03-1664.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).


Respectfully submitted,



Helen Lee, Reg. No. 39,270

Dated: March 30, 2007

NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Corporate Intellectual Property – R338  
P. O. Box 8097  
Emeryville, CA 94662-8097  
Tel: (510) 923-2192  
Fax: (510) 655-3542

<b>THE UNITED STATES PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>PTO/SB/08 (MODIFIED)</b>  <b>SHEET 1 OF 1</b>  	ATTORNEY DOCKET NO. PP001573.0101	APPLICATION NO. 09/914,279
	FIRST NAMED INVENTOR Derek O'Hagan	EXAMINER Unassigned
	FILING DATE 01/09/2002	
	CONFIRMATION NO. 2374	GROUP ART UNIT 1615

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE/ PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A1			
	A2			
	A3			
	A4			
	A5			

FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
	B1	WO 98/33487	08-06-1998	CHIRON CORPORATION	
	B2	GB 2 189 143 A	10-21-1987	RIBI IMMUNOCHEM	
	B3	WO 99/30737	06-24-1999	CHIRON CORPORATION	
	B4	WO 99/01579	01-14-1999	ISIS PHARMACEUTICALS	
	B5	WO 99/04761	02-04-1999	PHARMACIA & UPJOHN AB	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
EXAMINER INITIAL	REF. NO.	DESCRIPTION
	C1	
	C2	
	C3	
	C4	
	C5	

EXAMINER'S SIGNATURE	DATE CONSIDERED
----------------------	-----------------